SCHEMBL832201

SCHEMBL832201

CCOC(=O)c1cc2cc(Cl)c(Cl)cc2[nH]1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.69
KDM4E B2RXH2 3/20 0.67
ALDH1A1 P00352 3/20 0.67
HPGD P15428 3/20 0.67
RAB9A P51151 3/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
NPC1 O15118 2/20 0.67
LMNA P02545 2/20 0.67
KMT2A Q03164 2/20 0.67
MEN1 O00255 1/20 0.67
GLA P06280 1/20 0.67
GAA P10253 1/20 0.67
MAPT P10636 1/20 0.67
ATM Q13315 1/20 0.67
HSD17B10 Q99714 1/20 0.64
HTT P42858 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
HRH3 Q9Y5N1 1/20 0.59
MMP13 P45452 8/20 0.58
MMP2 P08253 6/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4049040 0.91 ALOX15 (0.66) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL1397976 0.90 ALOX15 (0.64) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL18331899 0.90 ALOX15 (0.64) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL4395738 0.88 ALOX15 (0.63) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL22760538 0.88 ALOX15 (0.63) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL23049705 0.88 ALOX15 (0.63) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL3276358 0.88 ALOX15 (0.63) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL18331701 0.88 ALOX15 (0.63) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL29641398 0.88 ALOX15 (0.63) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL3542541 0.88 ALOX15 (0.63) ALOX15KDM4EALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020244462-A1 INDOLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF 中国药科大学 2020-12-10 WO disclosed
WO-2017156181-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-09-14 WO disclosed
EP-1373204-B1 HETEROCYCLIC COMPOUNDS JANSSEN PHARMACEUTICALS INC (US) 2016-10-26 EP disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
EP-1390029-B1 PHENYLINDOLES FOR THE TREATMENT OF HIV IDENIX CAYMAN LTD (KY) 2009-12-16 EP disclosed
WO-2009032116-A1 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2009-03-12 WO disclosed
US-20080119485-A1 Novel Benzofurans and Indols ACTIVE BIOTECH AB (SE) 2008-05-22 US disclosed
WO-1999035130-A1 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER PHARMACEUTICALS INC. (JP) 1999-07-15 WO disclosed
WO-1999033801-A1 TRIPEPTIDYL PEPTIDASE INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1999-07-08 WO disclosed
EP-0914321-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS Smithkline Beecham S.p.A. (IT) 1999-05-12 EP disclosed
EP-0912511-A1 5-INDOLYL-2,4-PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION Smithkline Beecham S.p.A. (IT) 1999-05-06 EP disclosed
EP-0912560-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS Smithkline Beecham S.p.A. (IT) 1999-05-06 EP disclosed
WO-1998001423-A1 5-INDOLYL-2,4-PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION SMITHKLINE BEECHAM S.P.A. (IT) 1998-01-15 WO disclosed
WO-1998001445-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS SMITHKLINE BEECHAM S.P.A. (IT) 1998-01-15 WO disclosed
WO-1998001443-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS SMITHKLINE BEECHAM S.P.A. (IT) 1998-01-15 WO disclosed
EP-0802902-A1 INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF OSTEOPOROSIS Smithkline Beecham S.p.A. (IT) 1997-10-29 EP disclosed
WO-1996021644-A1 INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF OSTEOPOROSIS SMITHKLINE BEECHAM S.P.A. (IT) 1996-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 ALOX15 2229/4885KDM4E 1061/4885ALDH1A1 1792/4885
US-20080119485-A1 Novel Benzofurans and Indols FOXM1, IKZF3, BRPF3 ALOX15 1907/4885KDM4E 1516/4885ALDH1A1 1710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.